Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review
Journal of the European Academy of Dermatology and Venereology2014Vol. 29(6), pp. 1063–1070
Citations Over TimeTop 10% of 2014 papers
Patrick Fleming, C. Roubille, Vincent Richer, Tara Starnino, Collette McCourt, Alexandra McFarlane, S. Siu, J. Kraft, Charles Lynde, Janet Pope, Stephanie Keeling, Jan Dutz, Louis Bessette, Robert Bissonnette, Boulos Haraoui, Wayne Gulliver
Abstract
Adalimumab, etanercept and ustekinumab were associated with statistically significant reductions in depressive symptom scores using various scales in patients with moderate-to-severe psoriasis.
Related Papers
- → Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria(2015)40 cited
- → Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry(2015)12 cited
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → Adalimumab and etanercept adherence, persistence and switch in the treatment of psoriatic arthritis: 10-year real-life analysis(2019)8 cited